Literature DB >> 11487525

An alternative pathway for metabolism of leukotriene D(4): effects on contractions to cysteinyl-leukotrienes in the guinea-pig trachea.

M Bäck1, M Kumlin, I A Cotgreave, S E Dahlén.   

Abstract

Contractions of guinea-pig tracheal preparations to cysteinyl-leukotrienes (LTC(4), LTD(4) and LTE(4)) were characterized in organ baths, and cysteinyl-leukotriene metabolism was studied using radiolabelled agonists and RP-HPLC separation. In the presence of S-hexyl GSH (100 microM) the metabolism of [(3)H]-LTC(4) into [(3)H]-LTD(4) was inhibited and the LTC(4)-induced contractions were resistant to CysLT(1) receptor antagonism but inhibited by the dual CysLT(1)/CysLT(2) receptor antagonist BAY u9773 (0.3 - 3 microM) with a pA(2)-value of 6.8+/-0.2. In the presence of L-cysteine (5 mM), the metabolism of [(3)H]-LTD(4) into [(3)H]-LTE(4) was inhibited and the LTD(4)-induced contractions were inhibited by the CysLT(1) receptor antagonist ICI 198,615 (1 - 10 nM) with a pA(2)-value of 9.3+/-0.2. However, at higher concentrations of ICI 198,615 (30 - 300 nM) a residual contraction to LTD(4) was unmasked, and this response was inhibited by BAY u9773 (1 - 3 microM). In the presence of the combination of S-hexyl GSH with L-cysteine, the LTD(4)-induced contractions displayed the characteristics of the LTC(4) contractile responses, i.e. resistant to CysLT(1) receptor antagonism, increased maximal contractions and slower time-course. This qualitative change of the LTD(4)-induced contraction was also observed in the presence of S-decyl GSH (100 microM), GSH (10 mM) and GSSG (10 mM). S-hexyl GSH, S-decyl GSH, GSH and GSSG all stimulated a formation of [(3)H]-LTC(4) from [(3)H]-LTD(4). In conclusion, GSH and GSH-related compounds changed the pharmacology of the LTD(4)-induced contractions by stimulating the conversion of LTD(4) into LTC(4). Moreover, the results indicate that, in addition to the metabolism of LTC(4) into LTD(4) and LTE(4), also the formation of LTC(4) from LTD(4) may regulate cysteinyl-leukotriene function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487525      PMCID: PMC1572884          DOI: 10.1038/sj.bjp.0704180

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

Review 1.  Pharmacological characterization of leukotriene receptors.

Authors:  S E Dahlén
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes.

Authors:  M Bäck; X Norel; L Walch; J Gascard; G Mazmanian; S Dahlén; C Brink
Journal:  Eur J Pharmacol       Date:  2000-08-11       Impact factor: 4.432

3.  Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes.

Authors:  M Bäck; X Norel; L Walch; J Gascard; V de Montpreville; S Dahlén; C Brink
Journal:  Eur J Pharmacol       Date:  2000-08-11       Impact factor: 4.432

4.  Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.

Authors:  H P Nothacker; Z Wang; Y Zhu; R K Reinscheid; S H Lin; O Civelli
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

5.  How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?

Authors:  D MacKay
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

6.  Characterization of the human cysteinyl leukotriene 2 receptor.

Authors:  C E Heise; B F O'Dowd; D J Figueroa; N Sawyer; T Nguyen; D S Im; R Stocco; J N Bellefeuille; M Abramovitz; R Cheng; D L Williams; Z Zeng; Q Liu; L Ma; M K Clements; N Coulombe; Y Liu; C P Austin; S R George; G P O'Neill; K M Metters; K R Lynch; J F Evans
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

7.  The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.

Authors:  J Takasaki; M Kamohara; M Matsumoto; T Saito; T Sugimoto; T Ohishi; H Ishii; T Ota; T Nishikawa; Y Kawai; Y Masuho; T Isogai; Y Suzuki; S Sugano; K Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2000-08-02       Impact factor: 3.575

8.  Metabolism of leukotriene C3 in the guinea pig. Identification of metabolites formed by lung, liver, and kidney.

Authors:  S Hammarström
Journal:  J Biol Chem       Date:  1981-09-25       Impact factor: 5.157

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Inhibition of leukotriene C and leukotriene D biosynthesis.

Authors:  L Orning; S Hammarström
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

View more
  2 in total

1.  Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle.

Authors:  Laurence Walch; Xavier Norel; Magnus Bäck; Jean-Pierre Gascard; Sven-Erik Dahlén; Charles Brink
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients.

Authors:  Nicola Scichilone; Salvatore Battaglia; Alida Benfante; Vincenzo Bellia
Journal:  Clin Interv Aging       Date:  2013-10-02       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.